Urogynecological diseases, including pelvic organ prolapse (POP) and urinary incontinence (UI), significantly affect the quality of women’s life. The POP affects more than half of women over 50 years of age. The risk of UI depends on mechanisms resulting from three streams: ageing of the body, number of pregnancies and deliveries, as well as obesity. These are also possible points of potential interventions for prevention and treatment of urinary incontinence. Pregnancy affects the biomechanical properties of pelvic soft tissues. In addition, the loss of collagen in the ageing process is a natural process and collagen degradation is not compensated for by sufficient synthesis. Providing this protein from the outside may therefore slow down the degradation processes.
Assuming that tropocollagen I mesotherapy may be an alternative to surgical treatment of urinary incontinence, a pilot study was conducted in a group of 5 women with confirmed urinary incontinence. MD-Matrix and MD-Muscle collagens from Guna were used in the form of periurethral, transvaginal and suprapubic subcutaneous injections – mesotherapy. Four series of treatments were performed at 14–21 day intervals, using the preparations alternately, starting with MD-Matrix. According to the latest reports, improving the structure of the pelvic floor tissues may be a key strategy for the treatment of UI.
The preliminary results indicate that injectable tropocollagen may be effective in reducing the severity of urinary incontinence, and thus in improving the quality of life in women with already diagnosed UI, both in menopausal transition and after menopause.